Clinical Trial Update: A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of PEP07, a Checkpoint Kinase 1 (CHK1) inhibitor, is currently recruiting in patients with acute myeloid leukemia and mantle cell lymphoma. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• PEP07 (checkpoint kinase 1 inhibitor)

Snippet

Sponsor: PharmaEngine | Conditions: Acute Myeloid Leukemia, Lymphoma, Mantle-Cell | Phase 1 | Status: RECRUITING